An Update on Hepatocellular Carcinoma. Ed Gane NZ Liver Transplant Unit
|
|
- Clyde Robbins
- 5 years ago
- Views:
Transcription
1 An Update on Hepatocellular Carcinoma Ed Gane NZ Liver Transplant Unit
2 Hepatocellular Carcinoma has a High Burden of Disease APSCVIR March 2018 Lung Liver Colon/Rectal Stomach Breast Cervix Uteri Esophagus Bladder Non-Hodgkin's Lymphoma Oral Cavity Ovary Corpus Uteri Global Deaths from Cancer 204, , , , , , , , , , ,000 1,690, , , , ,000 1,000,000 1,200,000 1,400,000 1,600,000 1,800,000 HCC is 3 rd most common cancer HCC is 2 nd most common cancer-related death 1. Parkin DM, et al. CA Cancer J Clin. 2005;55: Pons-Renedo F, et al. Med Gen Med. 2003;5:11. iacentre/factsheets/fs297/en/. Accessed 16 April
3 # HCCs per annum Aetiology of HCC in New Zealand 2315 new HCC cases referred to the NZLTU HCC MDM HCV HBV NASH ALD Other Nov 2017-Nov 2018 APSCVIR March
4 # HCCs per annum Current trend due to aging untreated HCV cohort 100 HCV APSCVIR March Nov 2017-Nov
5 Pan-genotypic DAAs will reverse this trend 60,000 50,000 40,000 30,000 20,000 10,000 - Total Total Infected Cases Cases (Viremic) (Viremic) New Zealand New Zealand Liver Related Deaths New Zealand Baseline IFN Baseline DAAs IFN G1 only DAAs all all Genotypes Baseline IFN DAAs Baseline G1 IFN only DAAs all Genotypes HCC New Zealand Decompensated Cirrhosis New Zealand , Baseline IFN DAAs Baseline G1 only IFN DAAs all all Genotypes Baseline IFN Baseline DAAs G1 IFN only DAAs all Genotypes APSCVIR March 2018
6 # HCCs per annum Future trend will be due to the obesity epidemic 40 NASH % increase in NAFLD-HCC cases over the last decade 6
7 Liver cancer from HBV neonatal vaccination HBV remains the leadiing case of HCC in NZ despite universal neonatal vaccination since Trans-Tasman Lecture AGW 2018
8 ...reflecting increasing migration to New Zealand from countries with endemic HBV infection 30% 20% Chinese, SE Asian Pacific Islander 10% Within 20 years, 40% New Zealand population with be either Asian or Polynesian Trans-Tasman Lecture AGW % Source:
9 Current diagnosis of HCC
10 Updated Radiological Diagnostic Criteria for HCC (LiRADS) 10
11 Updated Radiological Diagnostic Criteria for HCC (LiRADS)
12 Management of HCC
13 EASL Updated BCLC Clinical Staging Criteria 13
14 EASL Updated BCLC Clinical Staging Criteria How to evaluate suitability for resection EASL Clinical Practice Guidelines
15 EASL Updated BCLC Clinical Staging Criteria Ablation is first line for small HCCs 1. Meta-analysis of 17 studies 3996 patients underwent resection 4424 patients underwent RFA OS Overall survival, DFS, disease free survival RFA has similar quality-adjusted life-expectancy but at lower cost than resection for patients with up to three nodules 3 cm Cucchetti et al, JHep
16 EASL Updated BCLC Clinical Staging Criteria Ablation is first line for small HCCs 2. NZLTU Data 1 year 3 year 5 year OLT (n = 145) 88% 77 % 73% Resection (n = 190) 88% 64% 54% Ablation (n = 109) 95% 72% 50% Wu L, et al. HPB 2018; 20:
17 Screening for HCC in patients infected with HBV Treatment determines Recurrence Rate at NZLTU 1 year 3 year 5 year OLT (n = 121) 97% 89% 84% Resection (n = 190) 66% 43% 35% Ablation (n = 109) 73% 33% 19% Wu L, et al. HPB 2018; 20:
18 Transplant Criteria for HCC
19 Overall Survival (%) Changing Criteria for Transplant for HCC 1. Milan Criteria ( ) - (i) Single tumour 5 cm or (ii) 2 or 3 tumours 3cm Based on small single centre study at National Cancer Institute, Milan - 48 patients with HBV or HCV cirrhosis transplanted for small HCC 100 Criteria Met Mazzafero, et al, NEJM Criteria Not Limitations 60 Met of Milan Criteria Too P< restrictive Excludes 20 patients with reasonable survival P=0.01 by the Log-Rank Test Within Milan Outside Milan Months After Transplantation Within Milan Outside Milan Sensitivity of pre-operative imaging improved 3 3
20 Survival Distribution Function Changing Criteria for Transplant for HCC 1. Milan Criteria ( ) - (i) Single tumour 5 cm or (ii) 2 or 3 tumours 3cm 2. UCSF Criteria ( ) - (i) Single tumour 6.5 cm or (ii) 2 or 3 tumours 4.5 cm (total diameter <8) Based at UCSF between patients transplanted for HCC 0.8 Within Milan (46) 0.6 Within UCSF (60) Outside UCSF (10) 0.0 Yao, et al, Liver Transpl 2002; 8: Year After Liver Transplantation Meeting New UCSF Staging Criteria Yes: No:
21 Changing Criteria for Transplant for HCC 1. Milan Criteria ( ) - (i) Single tumour 5 cm or (ii) 2 or 3 tumours 3 cm 2. UCSF Criteria ( ) - (i) Single tumour 6.5 cm or (ii) 2 or 3 tumours 4.5 cm (total diameter <8) 3. Extended Criteria with Downstaging Protocol (2018) Entry Criteria (before loco-regional therapy) (i) 1 tumour 8 cm or (ii) 2 or 3 tumours 5 cm or (iii) 4 or 5 tumours 3cm (total diameter <8) Listing Criteria (after loco-regional therapy) (i) Within UCSF or (ii) Milan Criteria (centre-dependent) - Wait 3 months prior to listing - Wait 6 months until provide MELD Exception points - DELIST if progresses outside Milan Criteria
22 Downstaging of HCC before Liver Transplant 118 patients down-staged to within UCSF criteria compared to 488 patients not down-staged and within Milan criteria (i) Post-transplant Survival (HCC Recurrence) (ii) Pre-transplant Drop-out (HCC progression) Within Milan P=0.04 P=0.69 Within Milan Yao F, et al. Hepatology 2015; 61:
23 Cumulative Survival (%) Downstaging of HCC before Liver Transplant Impact on response to downstaging on outcomes 543 outside UCSF criteria underwent downstaging pretransplant HCC down-staged to within UCSF in 422 pts ( UNOS-DS ) HCC remained outside UCSF in 121 pts ( AC-DS ) AFP predicted survival in down-staged patients Mehtra N, et al. AASLD 2018 Abstract # Months Post-transplant
24 NZLTU Downstaging Protocol Outside UCSF Within entry criteria* TACE Downstaged within Milan Observed 3 months Listed Observed 3 months +22 MELD points +2 points q3 mthly Entry Criteria 1 8cm or 2-3 5cm or 4-5 3cm AND Total 8cm 3 monthly restaging with CT/MRI + AFP DELIST if exceeds Milan or if AFP >400?
25 Any there any new systemic treatments for Advanced HCC?
26 Emerging Therapies for Advanced HCC 1. Small molecules targeting tumour pathways Anti-proliferative Anti-angiogenic 2. Immune checkpoint inhibitors 3. Oncolytic viruses APSCVIR March 2018 WHAD, July 28th
27 Landscape of Systemic Treatment 2008 Agent Class Line of Treatment Status Result Sorafenib TKI First line FDA Approved 2005 Median OS 10.7 mos 27
28 Survival Probability ( %) Sorafenib: the first approved therapy for Advanced HCC SHARP study of sorafenib, an oral tyrosine kinase inhibitor 602 patients with advanced HCC (28 from Auckland) 100 Sorafenib (n=299) Median: 10.8 mo (95% CI: ) 75 Placebo (n=303) Median: 7.9 mo (95% CI: ) 50 APSCVIR March Patients at Risk Sorafenib Placebo HR (95% CI): 0.69 ( ) P= * Months Llovet JM, et al. N Engl J Med Jul 24;359(4):
29 APSCVIR March 2018 Currently $9,000 per month, unfunded
30 Landscape of Systemic Treatment Agent Class Line of Treatment Status Result Sorafenib TKI First line Lenvatinib TKI First line Nivolumab Anti-PD-1 Second line Regorafenib TKI Second line Cabozantinib Anti-MET Second line Ramucirumab Anti-VEGFR2 Second line FDA Approved 2005 FDA Approved 2012 FDA Approved 2017 FDA Approved 2017 Currently under FDA Review Currently under FDA Review Median OS 10.7 mos Median OS 13.6 mos Median OS 13.2 mos phase 1/2 Median OS 10.6 mos Median OS 10.2 mos Press Release POSITIVE 30
31 Phase III REFLECT study of Lenvatinib a Multikinase Inhibitor in Advanced HCC Probability of PFS APSCVIR March patients with advanced HCC were randomized 2:1 to sorafenib or lenvatinib 8 mg (< 60 kg)/12 mg ( 60 kg) In patients with advanced HR: 0.66 (95% HCC, CI: ) Log-rank test: P < Lenvatinib 0.3 improved progression- 0.2 free 0.1 survival compared to Sorafenib Mos Pts at Risk, n Median, mos (95% CI) Lenvatinib: 7.4 ( ) Sorafenib: 3.7 ( ) Cheng AL, et al. ASCO Abstract
32 Phase III CELESTIAL study of Carbozantinib a MET Inhibitor in Advanced HCC 760 patients with advanced HCC who had failed sorafenib were randomized 2:1 to 60 mg of cabozantinib or placebo APSCVIR March In patients who failed Sorafenib, Carbozantinib improved survival Median survival 15 months Hazard Ratio 0.44; P < Median survival 8 months Abou-Alfa G, et al, ASCO-GI;
33 Immunotherapy with Checkpoint inhibitors Phase II CheckMate study of Nivolumab (anti-pd1) 311 compensated cirrhotic patients with advanced HCC received Nivolumab 0.3mg/kg IV every 2 weeks Sorafenib failures APSCVIR March decompensated cirrhotics Tumour response in 55% Median survival 8 months Similar safety profile Kudo M, et al AASLD Abstract LB#2 Disease response in 68% Median survival 15 months (cf 6 months historical) 4% discontinued, no treatment-related deaths El-Khoueiry A, et al Lancet 2017; 389:
34 Check-point inhibitor combined with other agents 1. Anti PD-1 + Isatuximab (anti-cd38 mab) 2. Anti PD-1 + Cabozantinib (multi-tyrosine kinase inhibitor) 3. Anti-PD-1 + Ipilimumab 4. Anti-PD-1 + Ipilimumab + cabozantinib 5. Anti PD-1 + CBT-101 (c-met inhibitor) 6. Anti PD-1 + Lenvatanib (VEGFR and FGFR inhibitor) 7. Anti-PD-L1 + Bevacizumab (anti-vegf) 8. Anti-PD-L1 + Ramucirumab (anti-vegf-r2 Ab 9. Anti-PD-L1 plus tremelimumab (anti-ctla-4 mab) 10. Anti PD-1 + NC280 (c-met inhibitor) 11. Anti PD-1 + galunisertib (TGF-b inhibitor) 12. Anti PD-1 + NIS793 (anti TGF-b mab) 13. Anti-CTLA-4 mab + MGN1703 (TLR agonist) 14. Anti-PD-L1 + AZD4635 (adenosine A2A receptor antagonist) 34
35 Immunotherapy with an Oncolytic Virus Pexa-Vec: genetically modified vaccinia virus APSCVIR March 2018 A frozen viral suspension Administered IV and/or IT 35 35
36 Immunotherapy with an Oncolytic Virus Pexa-Vec: genetically modified vaccinia virus 8wks 20mth s Infects and destroys distant HCC mets 12 wks 6 cm APSCVIR March 2018 Park et al, Lancet Oncol
37 Screening for HCC in patients infected with HBV Most patients receive palliative therapy NZLTU (n=2161) TACE 12% 51% Palliative 11% 11% 15% Ablation Transplant Resection APSCVIR March
38 Nothing About Us Without Us to improve the way we manage our patients with advanced HCC NAUWOU Workshops
39 NAUWOS output Unmet needs Emotional impact of diagnosis and short survival Language/cultural barriers Social/financial impact (sole income in large whanau) Changes New clinic (not Friday afternoon) Closer community follow up Early palliative care APSCVIR March
40 Management of Hepatocellular Carcinoma requires a Multidisciplinary Approach Interventional radiology Diagnostic Radiology Hepatology Hepatobiliary and Transplant Surgery Patient with HCC Medical Oncology Pathology Radiation Oncology Primary care Provider Palliative Care
41 Hepatocellular Carcinoma in Asia-Pacific Current Problems Huge disease burden in Asia Pacific Region Due to endemic HBV infection Increasing 10% per annum from HCV and obesity epidemic Unmet medical need >90% patients have cirrhosis Transplant is limited resource Most are detected late, no curative options Sorafenib is expensive and has poor safety/efficacy profile APSCVIR March
42 Hepatocellular Carcinoma in Asia-Pacific Future Solutions 1. Earlier detection identification of those at-risk populations uptake of HCC surveillance 2. Safer, more effective therapy Local ablation for early HCC Funded systemic therapy for advanced HCC 3. Better prevention HBV vaccination Wide access to HCV treatment Government strategies to reduce obesity APSCVIR March
43 Thank you! John McCall, Adam Bartlett Lucy Modhal, Andrew Holden Oonagh Lithgow, Veronica Henderson Anne Callaghan, Palliative Care Team The NAUWOU working group
New Therapies in HCC Bruno Sangro Clínica Universidad de Navarra. IdISNA. CIBERehd. Pamplona, Spain
New Therapies in HCC Bruno Sangro Clínica Universidad de Navarra. IdISNA. CIBERehd. Pamplona, Spain PHC 2018 - www.aphc.info EASL-EORTC Guidelines EASL EORTC Guidelines. J Hepatol. 2012;56:908-43. Systemic
More informationIl Tumore del Fegato Prospettive Future nel Trattamento dei Tumori Gastrointestinali
Il Tumore del Fegato Prospettive Future nel Trattamento dei Tumori Gastrointestinali Lorenza Rimassa Medical Oncology Unit Humanitas Cancer Center Humanitas Research Hospital Rozzano (Milano) Disclosures
More information12 AISF Special Conference Sorafenib: magnitude of benefit, side effects and stopping rules 9 years after approval
12 AISF Special Conference Sorafenib: magnitude of benefit, side effects and stopping rules 9 years after approval ARMANDO SANTORO Roma 10-6-2016 SORAFENIB APPROVAL 29 OCTOBER 2007 Marketing authorization
More informationAdvances in percutaneous ablation and systemic therapies for hepatocellular carcinoma
Advances in percutaneous ablation and systemic therapies for hepatocellular carcinoma Paris Hepatology Congress 2019 Pierre Nahon Service d Hépatologie Hôpital Jean Verdier Bondy Université Paris 13 INSERM
More informationThe Current Champion: Angiogenesis inhibitors
The Current Champion: Angiogenesis inhibitors Baek-Yeol RYOO University of Ulsan College of Medicine ASAN Medical Center Dept. of Oncology Seoul, Korea Survival probability Sorafenib: Overall Survival
More informationHCC: Is it an oncological disease? - No
June 13-15, 2013 Berlin, Germany Prof. Oren Shibolet Head of the Liver Unit, Department of Gastroenterology Tel-Aviv Sourasky Medical Center and Tel-Aviv University HCC: Is it an oncological disease? -
More informationAdvances in Systemic Therapy Hepatocellular Carcinoma (HCC) Dr ZEE Ying Kiat HASLD Conference Ho Chi Minh City, 18 December 2016
Advances in Systemic Therapy for Hepatocellular Carcinoma (HCC) Dr ZEE Ying Kiat HASLD Conference Ho Chi Minh City, 18 December 2016 Scope Background Staging and treatment strategies Current systemic therapy
More informationHepatitis B Virus-Related Hepatocellular Carcinoma Presenting at an Advanced Stage: Is it Preventable? Dr Tom Mules NZSG ASM 2018
Hepatitis B Virus-Related Hepatocellular Carcinoma Presenting at an Advanced Stage: Is it Preventable? Dr Tom Mules NZSG ASM 2018 HCC Males Females Ferlay et al. Cancer incidence and mortality worldwide:
More informationRiunione Monotematica A.I.S.F The future of liver diseases. HEPATIC NEOPLASMS The challenge for new drugs
Riunione Monotematica A.I.S.F. 2016 The future of liver diseases Milan 13 th -15 th October 2016 Centro Congressi Fondazione Cariplo HEPATIC NEOPLASMS The challenge for new drugs Massimo Iavarone Gastroenterology
More informationIl treatment plan nella terapia sistemica dell epatocarcinoma
Il treatment plan nella terapia sistemica dell epatocarcinoma M. Iavarone, MD PhD CRC A.M. e A. Migliavacca Center for the Study of Liver Disease Division of Gastroenterology and Hepatology Fondazione
More informationHepatocellular Carcinoma. Markus Heim Basel
Hepatocellular Carcinoma Markus Heim Basel Outline 1. Epidemiology 2. Surveillance 3. (Diagnosis) 4. Staging 5. Treatment Epidemiology of HCC Worldwide, liver cancer is the sixth most common cancer (749
More informationLatest Developments in the Treatment of Hepatocellular Carcinoma
Latest Developments in the Treatment of Hepatocellular Carcinoma Roniel Cabrera, MD MS Associate Professor of Medicine Director of Hepatology and Medical Director of Liver Transplantation Division of Gastroenterology,
More informationCurrent Standards of Care of Hepatocellular Carcinoma? Prof. Mohsen Mokhtar M.D Cairo Univ.
Current Standards of Care of Hepatocellular Carcinoma? Prof. Mohsen Mokhtar M.D Cairo Univ. Disclosures Honoraria Received : Amgen, Astra Zeneca, Bohrengier, Hikma,Hospira, GSK, Lilly, Merck, MSD, Novartis,
More informationHepatocellular Carcinoma (HCC): Who Should be Screened and How Do We Treat? Tom Vorpahl MSN, RN, ACNP-BC
Hepatocellular Carcinoma (HCC): Who Should be Screened and How Do We Treat? Tom Vorpahl MSN, RN, ACNP-BC Objectives Identify patient risk factors for hepatocellular carcinoma (HCC) Describe strategies
More informationSEQUENCING OF HCC TREATMENT. Dr. Amit G. Singal Medical Director, UT Southwestern Medical Center, USA
SEQUENCING OF HCC TREATMENT Dr. Amit G. Singal Medical Director, UT Southwestern Medical Center, USA February 2018 DISCLAIMER Please note: The views expressed within this presentation are the personal
More informationGuidelines for SIRT in HCC An Evolution
Guidelines for SIRT in HCC An Evolution 2 nd Asia Pacific Symposium on Liver- Directed Y-90 Microspheres Therapy 1st November 2014, Singapore The challenge of HCC Surgery is potentially curative in early
More informationA) PUBLIC HEALTH B) PRESENTATION & DIAGNOSIS
Hepatocellular Carcinoma HCC Updated November 2015 by: Dr. Mohammed Alghamdi (Medical Oncology Fellow, University of Calgary), April 2017 by Dr. Jenny Ko (Medical Oncologist, Abbotsford Centre, BC Cancer
More informationHepatocellular Carcinoma HCC Updated November 2015 by: Dr. Mohammed Alghamdi (Medical Oncology Fellow, University of Calgary)
Hepatocellular Carcinoma HCC Updated November 2015 by: Dr. Mohammed Alghamdi (Medical Oncology Fellow, University of Calgary) Staff Reviewers: Dr. Yoo Joung Ko (Medical Oncologist, Sunnybrook Odette Cancer
More informationFirst-line therapy for unresectable HCC:
ESMO GI Cancer Preceptorship 15 November 2017 Singapore First-line therapy for unresectable HCC: an oncologist s viewpoint Chiun Hsu, MD, PhD G raduate I n stitute of Oncology, National Taiwan Univers
More informationΗπατοκυτταρικός Καρκίνος Συστηματική Θεραπεία. Θωμάς Μακατσώρης Επίκ. Καθ. Παθολογίας-Ογκολογίας Ιατρική Σχολή Πανεπιστημίου Πατρών 11/5/2018
Ηπατοκυτταρικός Καρκίνος Συστηματική Θεραπεία Θωμάς Μακατσώρης Επίκ. Καθ. Παθολογίας-Ογκολογίας Ιατρική Σχολή Πανεπιστημίου Πατρών 11/5/2018 Advisory Board Disclosures Roche, Boeringer, Sanofi, Astra Zeneca,
More information3/22/2017. I will be discussing off label/investigational use of tivantinib for hepatocellular carcinoma.
Grant/Research Support - AbbVie, Conatus, Hologic, Intercept, Genfit, Gilead, Mallinckrodt, Merck, Salix, Shire, Vital Therapies Consultant AbbVie, Gilead, Merck Member, Scientific Advisory Board Vital
More informationAASLD Washington DC, USA Dr. Alexander Kim Chief Vascular and Interventional Radiology, Medstar Georgetown University Hospital
AASLD 2017 - Washington DC, USA Dr. Alexander Kim Chief Vascular and Interventional Radiology, Medstar Georgetown University Hospital THE CHANGING LANDSCAPE IN THE TREATMENT OF HCC DISCLAIMER Please note:
More informationManagement of HepatoCellular Carcinoma
9th Symposium GIC St Louis - 2010 Management of HepatoCellular Carcinoma Overview Pierre A. Clavien, MD, PhD Department of Surgery University Hospital Zurich Zurich, Switzerland Hepatocellular carcinoma
More informationThe Chronic Liver Disease Foundation (CLDF) and the International Coalition of Hepatology Education Providers (IC-HEP) present:
The Chronic Liver Disease Foundation (CLDF) and the International Coalition of Hepatology Education Providers (IC-HEP) present: Certified by: Provided by: Endorsed by: Hepatocellular Carcinoma HCC: Age
More informationHepatocellular Carcinoma: Transplantation, Resection or Ablation?
Hepatocellular Carcinoma: Transplantation, Resection or Ablation? Roberto Gedaly MD Chief, Abdominal Transplantation Transplant Service Line University of Kentucky Nothing to disclose Disclosure Objective
More informationManagement of advanced Hepatocellular carcinoma
Management of advanced Hepatocellular carcinoma V Di Martino* Acknowledgements to T Thevenot *Advisory board/lectures/travel facilities: Case report (1) Mr T. Philippe 55 yrs old Past IV drug user (1985)
More information9th Paris Hepatitis Conference
9th Paris Hepatitis Conference Paris, 12 January 2016 Treatment of hepatocellular carcinoma: beyond international guidelines Massimo Colombo Chairman Department of Liver, Kidney, Lung and Bone Marrow Units
More informationSelection Criteria and Insertion of SIRT into HCC Treatment Guidelines
Selection Criteria and Insertion of SIRT into HCC Treatment Guidelines 2 nd Asia Pacific Symposium on Liver- Directed Y-90 Microspheres Therapy 1st November 2014, Singapore Pierce Chow FRCSE PhD SIRT in
More informationTHE CHANGING LANDSCAPE IN THE TREATMENT OF HEPATOCELLULAR CARCINOMA (HCC)
MEETING SUMMARY EASL 2017, AMSTERDAM, THE NETHERLANDS APRIL 19 TH TO 23 RD 2017 DR JEAN-CHARLES NAULT JEAN VERDIER HOSPITAL, BONDY, FRANCE THE CHANGING LANDSCAPE IN THE TREATMENT OF HEPATOCELLULAR CARCINOMA
More informationAntiviral Therapy and Liver Cancer
Antiviral Therapy and Liver Cancer St. Petersburg, 070613 Markus Peck-Radosavljevic Gastroenterologie & Hepatologie AKH & Medizinische Universität Wien HCC Study Group Medizinische Universität Wien Prevention
More informationLiver transplantation: Hepatocellular carcinoma
Liver transplantation: Hepatocellular carcinoma Alejandro Forner BCLC Group. Liver Unit. Hospital Clínic. University of Barcelona 18 de marzo 2015 3r Curso Práctico de Transplante de Órganos Sólidos Barcelona
More informationLiver and Biliary Tract Cancers Critical Review
Liver and Biliary Tract Cancers Critical Review Lorenza Rimassa Oncologia Medica e Ematologia Humanitas Cancer Center Humanitas Research Hospital Rozzano (Milano) Critical review Oral presentations Melero
More informationHepatocellular Carcinoma: A major global health problem. David L. Wood, MD Interventional Radiology Banner Good Samaritan Medical Center
Hepatocellular Carcinoma: A major global health problem David L. Wood, MD Interventional Radiology Banner Good Samaritan Medical Center Hepatocellular Carcinoma WORLDWIDE The #2 Cancer Killer Overall cancer
More informationIS THERE A DIFFERENCE IN LIVER CANCER RATES IN PATIENTS WHO RECEIVE TREATMENT FOR HEPATITIS?
IS THERE A DIFFERENCE IN LIVER CANCER RATES IN PATIENTS WHO RECEIVE TREATMENT FOR HEPATITIS? Dr. Sammy Saab David Geffen School of Medicine, Los Angeles, USA April 2018 DISCLAIMER Please note: The views
More information蕾莎瓦 Nexavar 臨床試驗資料 (HCC 肝細胞癌 )
蕾莎瓦 Nexavar 臨床試驗資料 (HCC 肝細胞癌 ) 1 Sorafenib Improves Survival in Hepatocellular Carcinoma: Results of a Phase III Randomized, -Controlled Trial Josep M. Llovet, Sergio Ricci, Vincenzo Mazzaferro, Philip
More informationNew Insights: Systemic Therapy for Advanced Hepatocellular Carcinoma (HCC)
New Insights: Systemic Therapy for Advanced Hepatocellular Carcinoma (HCC) Thomas W.T. Leung Associate Director and Honorary Consultant Comprehensive Oncology Centre Hong Kong Sanatorium and Hospital Hong
More information3 Workshop on HCV THERAPY ADVANCES New Antivirals in Clinical Practice
3 Workshop on HCV THERAPY ADVANCES New Antivirals in Clinical Practice Rome, 13 December 2013 Management and monitoring of HCC in the future era of DAA s Prof. Massimo Colombo Chairman Department of Liver,
More information6/16/2016. Treating Hepatocellular Carcinoma: Deciphering the Clinical Data. Liver Regeneration. Liver Regeneration
Treating : Deciphering the Clinical Data Derek DuBay, MD Associate Professor of Surgery Director of Liver Transplant Liver Transplant and Hepatobiliary Surgery UAB Department of Surgery Liver Regeneration
More informationRenal Cell Carcinoma: Systemic Therapy Progress and Promise
Renal Cell Carcinoma: Systemic Therapy Progress and Promise Michael B. Atkins, M.D. Deputy Director, Lombardi Comprehensive Cancer Ctr Georgetown University Medical Center Everolimus Rini, Campbell, Escudier.
More informationTREATMENT FOR HCC AND CHOLANGIOCARCINOMA. Shawn Pelletier, MD
TREATMENT FOR HCC AND CHOLANGIOCARCINOMA Shawn Pelletier, MD Treatment for HCC Treatment strategies Curative first line therapy Thermal ablation vs Resection vs Transplant Other first line therapies TACE
More informationPamplona, junio de Futuro de la Hepatología: Cáncer Hepático. Bruno Sangro Clínica Universidad de Navarra. IDISNA. CIBERehd.
Pamplona, junio de 2008 Futuro de la Hepatología: Cáncer Hepático Bruno Sangro Clínica Universidad de Navarra. IDISNA. CIBERehd. Pamplona, Spain Etiología del Cáncer Hepático HBV HCV Alcohol NAFLD Iron
More informationNexavar in advanced HCC: a paradigm shift in clinical practice
Nexavar in advanced HCC: a paradigm shift in clinical practice Tim Greten Hanover Medical School, Germany Histopathological progression and molecular features of HCC Chronic liver disease Liver cirrhosis
More informationDevelopmental Therapeutics for HCC, Colorectal Cancer, and Pancreatic Cancer. Manish Sharma, MD Developmental Therapeutics Symposium April 20, 2018
Developmental Therapeutics for HCC, Colorectal Cancer, and Pancreatic Cancer Manish Sharma, MD Developmental Therapeutics Symposium April 20, 2018 Disclosure Information 23 rd Annual Developmental Therapeutics
More informationPaul Martin MD FACG. University of Miami
Paul Martin MD FACG University of Miami 1 Liver cirrhosis of any cause Chronic C o c hepatitis epat t s B Risk increases with Male gender Age Diabetes Smoking ~5% increase in HCV-related HCC between 1991-28
More informationScreening for HCCwho,
Screening for HCCwho, how and how often? Catherine Stedman Associate Professor of Medicine, University of Otago, Christchurch Gastroenterology Department, Christchurch Hospital HCC Global Epidemiology
More informationHepatocellular Carcinoma: Can We Slow the Rising Incidence?
Hepatocellular Carcinoma: Can We Slow the Rising Incidence? K.Rajender Reddy M.D. Professor of Medicine Director of Hepatology Medical Director of Liver Transplantation University of Pennsylvania Outline
More informationTumor incidence varies significantly, depending on geographical location.
Hepatocellular carcinoma is the 5 th most common malignancy worldwide with male-to-female ratio 5:1 in Asia 2:1 in the United States Tumor incidence varies significantly, depending on geographical location.
More informationLiver Cancer. Su Jong Yu, M.D. Department of Internal Medicine, Liver Research Institute, Seoul National University College of Medicine
Liver Cancer Su Jong Yu, M.D. Department of Internal Medicine, Liver Research Institute, Seoul National University College of Medicine Primary Liver Cancer Hepatocellular carcinoma (HCC) : > 80% Derived
More informationUPDATE OF EASL CLINICAL PRACTICE GUIDELINES: MANAGEMENT OF HEPATOCELLULAR CARCINOMA*
UPDATE OF EASL CLINICAL PRACTICE GUIDELINES: MANAGEMENT OF HEPATOCELLULAR CARCINOMA* Dr. Catherine Frenette Medical Director of Liver Transplantation, Scripps Green Hospital, La Jolla, CA, USA May 2018
More informationWorldwide Causes of HCC
Approach to HCV Treatment in Patients with HCC JORGE L. HERRERA, MD, MACG UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE Worldwide Causes of HCC 60% 50% 40% 54% 30% 20% 10% 31% 15% 0% Hepatitis B Hepatitis
More informationHepatocellular Carcinoma: Diagnosis and Management
Hepatocellular Carcinoma: Diagnosis and Management Nizar A. Mukhtar, MD Co-director, SMC Liver Tumor Board April 30, 2016 1 Objectives Review screening/surveillance guidelines Discuss diagnostic algorithm
More informationHepatocellular Carcinoma Surveillance
Amit G. Singal, MD, MS Hepatocellular Carcinoma Surveillance Postgraduate Course: Challenges in Management of Common Liver Diseases 308 1 Patient Case 69 year-old otherwise healthy male with compensated
More informationProfessor Norbert Bräu
Sixth Annual BHIVA Conference for the Management of HIV/Hepatitis Co-Infection in collaboration with BASL and BVHG Professor Norbert Bräu James J Peters VA Medical Center, New York, USA COMPETING INTEREST
More informationSurveillance for HCC Who, how Diagnosis of HCC Surveillance for HCC in Practice
Surveillance for Hepatocellular Carcinoma Hashem B. El-Serag, MD, MPH Dan L. Duncan Professor of Medicine Chief, Gastroenterology and Hepatology Houston VA & Baylor College of Medicine Houston, TX Outline
More information6 Riunione Monotematica A.I.S.F NASH malattia epatica, oncologica e cardiovascolare
6 Riunione Monotematica A.I.S.F. 2015 NASH malattia epatica, oncologica e cardiovascolare Modena, 9 ottobre 2015 Massimo Colombo NAFLD e HCC: caratteristiche distintive Chairman Department of Liver, Kidney,
More informationCelsion Symposium New Paradigms in HCC Staging: HKLC vs. BCLC Staging
Celsion Symposium New Paradigms in HCC Staging: HKLC vs. BCLC Staging Ronnie T.P. Poon, MBBS, MS, PhD Chair Professor of Hepatobiliary and Pancreatic Surgery Chief of Hepatobiliary and Pancreatic Surgery
More informationExperience with pre-transplant antiviral treatment: PEG/RBV and DAA. Xavier Forns, MD Liver Unit Hospital Clínic IDIBAPS and CIBREHD Barcelona
Experience with pre-transplant antiviral treatment: PEG/RBV and DAA Xavier Forns, MD Liver Unit Hospital Clínic IDIBAPS and CIBREHD Barcelona Interferon-free regimens G1b nulls Asunaprevir (PI) + Daclatasvir
More informationL epatocarcinoma nel Stefano Fagiuoli U.S.C. Gastroenterologia Epatologia e Trapiantologia ASST Papa Giovanni XXIII - Bergamo
L epatocarcinoma nel 2018 Stefano Fagiuoli U.S.C. Gastroenterologia Epatologia e Trapiantologia ASST Papa Giovanni XXIII - Bergamo EASL 2018 HCC Guidelines Topics 1. Epidemiology and risk factors 2. Prevention
More informationSurveillance for Hepatocellular Carcinoma
Surveillance for Hepatocellular Carcinoma Marion G. Peters, MD John V. Carbone, MD, Endowed Chair Professor of Medicine Chief of Hepatology Research University of California San Francisco Recorded on April
More informationDisclosure. Speaker name: Prof. Maciej Pech I have the following potential conflicts of interest to report:
Disclosure Speaker name: Prof. Maciej Pech I have the following potential conflicts of interest to report: Consulting Employment in industry Stockholder of a healthcare company Owner of a healthcare company
More informationReconsidering Liver Transplantation for HCC in a Era of Organ shortage
Reconsidering Liver Transplantation for HCC in a Era of Organ shortage Professor Didier Samuel Centre Hépatobiliaire Inserm-Paris Sud Research Unit 1193 Departement Hospitalo Universitaire Hepatinov Hôpital
More informationLiver Cancer: Epidemiology and Health Disparities. Andrea Goldstein NP, MS, MPH Scientific Director Onyx Pharmaceuticals
Liver Cancer: Epidemiology and Health Disparities Andrea Goldstein NP, MS, MPH Scientific Director Onyx Pharmaceuticals 1. Bosch FX, et al. Gastroenterology. 2004;127(5 suppl 1):S5-S16. 2. American Cancer
More informationHepatocellular Carcinoma in Qatar
Hepatocellular Carcinoma in Qatar K. I. Rasul 1, S. H. Al-Azawi 1, P. Chandra 2 1 NCCCR, 2 Medical Research Centre, Hamad Medical Corporation, Doha, Qatar Abstract Objective The main aim of this study
More informationHBV in New Zealand Community HBV screening to long-term follow-up
HBsAg+ icteric hepatitis (n) % anti-hbcore+ 26/9/214 HBV in New Zealand Community HBV screening to long-term follow-up John Hornell, CEO, A registered charitable trust whose mission is: To improve health
More informationHepatocellular Carcinoma (HCC): Burden of Disease
Hepatocellular Carcinoma (HCC): Burden of Disease Blaire E Burman, MD VM Hepatology Hepatocellular Carcinoma (HCC) Primary HCCs most often arise in the setting of chronic inflammation, liver damage, and
More informationRETHINKING OUR APPROACH TO INTERMEDIATE-SIZE HCC
SATELLITE SYMPOSIUM Emerging Horizons in HCC: From Palliation to Cure RETHINKING OUR APPROACH TO INTERMEDIATE-SIZE HCC Professor Riccardo Lencioni, MD, FSIR, EBIR University of Pisa School of Medicine,
More informationHEPATOCELLULAR CARCINOMA: SCREENING, DIAGNOSIS, AND TREATMENT
HEPATOCELLULAR CARCINOMA: SCREENING, DIAGNOSIS, AND TREATMENT INTRODUCTION: Hepatocellular carcinoma (HCC): Fifth most common cancer worldwide Third most common cause of cancer mortality In Egypt: 2.3%
More informationThe impact of the treatment of HCV in developing Hepatocellular Carcinoma
The impact of the treatment of HCV in developing Hepatocellular Carcinoma Paul Y Kwo, MD Professor of Medicine Medical Director, Liver Transplantation Gastroenterology/Hepatology Division Indiana University
More informationWorldwide Causes of HCC
Approach to HCV Treatment in Patients with HCC Mark W. Russo, MD, MPH, FACG Carolinas HealthCare System Charlotte Worldwide Causes of HCC 60% 50% 40% 30% 20% 10% 0% 54% 31% 15% Hepatitis B Hepatitis C
More informationHepatobiliary Malignancies Retrospective Study at Truman Medical Center
Hepatobiliary Malignancies 206-207 Retrospective Study at Truman Medical Center Brandon Weckbaugh MD, Prarthana Patel & Sheshadri Madhusudhana MD Introduction: Hepatobiliary malignancies are cancers which
More informationHCC: Epidemiology. Update on treatment of advanced hepatocellular carcinoma. Incidence of HCC is increasing
Update on treatment of advanced hepatocellular carcinoma Jean-Luc Raoul Centre E Marquis Rennes, Brittany France HCC: Epidemiology Europe - USA: C virus, alcohol obesity, iron Europe: 4 deaths / year 6
More informationWHAT IS THE BEST APPROACH FOR TRANS-ARTERIAL THERAPY IN HCC?
WHAT IS THE BEST APPROACH FOR TRANS-ARTERIAL THERAPY IN HCC? Dr. Alexander Kim Chief, Vascular and Interventional Radiology, Medstar Georgetown University Hospital, USA DISCLAIMER Please note: The views
More informationManagement of Hepatocellular Carcinoma in Africa CWN Spearman
Management of Hepatocellular Carcinoma in Africa CWN Spearman Division of Hepatology Department of Medicine Faculty of Health Sciences University of Cape Town Nothing to disclose Disclosures HCC in Africa
More informationSTOP Hepatocellular Carcinoma
STOP Hepatocellular Carcinoma Laura Tenner MD MPH, Amit G. Singal MD MS, Mamta Jain MD, Barbara Turner MD, Barbara Riske MS ReACH Center and Dept of Medicine UT Health San Antonio Dept of Medicine UT Southwestern
More informationViral hepatitis and Hepatocellular Carcinoma
Viral hepatitis and Hepatocellular Carcinoma Hashem B. El-Serag, MD, MPH Dan L. Duncan Professor of Medicine Chief, Gastroenterology and Hepatology Houston VA & Baylor College of Medicine Houston, TX Outline
More informationLife After SVR for Cirrhotic HCV
Life After SVR for Cirrhotic HCV KIM NEWNHAM MN, NP CIRRHOSIS CARE CLINIC UNIVERSITY OF ALBERTA Objectives To review the benefits of HCV clearance in cirrhotic patients To review some of the emerging data
More informationTreatment of Hepatocellular Carcinoma. Andrew J. Muir, MD MHS Division of Gastroenterology Duke University Medical Center
Treatment of Hepatocellular Carcinoma Andrew J. Muir, MD MHS Division of Gastroenterology Duke University Medical Center Epidemiology of HCC: world The 5 th most common cancer worldwide > 500, 000 new
More informationCurrent Trends in Melanoma Theresa Medina, MD UCD Cutaneous Oncology
Current Trends in Melanoma Theresa Medina, MD UCD Cutaneous Oncology Overview Melanoma incidence and prevention Approach to surgical management of early melanoma Landscape of Advanced Melanoma Therapy
More informationCisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer. Valle J et al. N Engl J Med 2010;362(14):
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer Valle J et al. N Engl J Med 2010;362(14):1273-81. Introduction > Biliary tract cancers (BTC: cholangiocarcinoma, gall bladder cancer,
More informationTargeted and immunotherapy in RCC
Targeted and immunotherapy in RCC Treatment options Surgery (radical VS partial nephrectomy) Thermal ablation therapy Surveillance Immunotherapy Molecular targeted therapy Molecular targeted therapy Targeted
More informationSIRT for Intermediate and Advanced HCC
Pamplona, junio de 2008 SIRT for Intermediate and Advanced HCC Bruno Sangro Clínica Universidad de Navarra. CIBERehd. Pamplona, Spain 90 Y-RE MRI SPECT FUSION 90 Y-RE = Yttrium-90 radioembolization Sangro
More informationWhen patients fail on molecular targeted therapy: what to do in 2013
When patients fail on molecular targeted therapy: what to do in 2013 For 3 rd APASAL HCC conference on 23 Nov 2013 Dr. Stephen L. Chan Department of Clinical Oncology The Chinese University of Hong Kong
More informationSurgical management of HCC. Evangelos Prassas Hepatobiliary and Pancreatic Surgery / Liver Transplantation Kings College Hospital / London
Surgical management of HCC Evangelos Prassas Hepatobiliary and Pancreatic Surgery / Liver Transplantation Kings College Hospital / London Global distribution of HCC and staging systems WEST 1. Italy (Milan,
More informationHepatitis C: Difficult-to-treat Patients 11th Paris Hepatology Conference 16th January 2018 Stefan Zeuzem, MD University Hospital, Frankfurt, Germany
Hepatitis C: Difficult-to-treat Patients 11th Paris Hepatology Conference 16th January 2018 Stefan Zeuzem, MD University Hospital, Frankfurt, Germany PHC 2018 - www.aphc.info Disclosures Advisory boards:
More informationUnmet needs in intermediate HCC. Korea University Guro Hospital Ji Hoon Kim
Unmet needs in intermediate HCC Korea University Guro Hospital Ji Hoon Kim BCLC HCC Stage 0 PST 0, Child Pugh A Stage A C PST 0 2, Child Pugh A B Stage D PST > 2, Child Pugh C Very early stage (0) 1 HCC
More informationImmunotherapy for the Treatment of Melanoma. Marlana Orloff, MD Thomas Jefferson University Hospital
Immunotherapy for the Treatment of Melanoma Marlana Orloff, MD Thomas Jefferson University Hospital Disclosures Immunocore and Castle Biosciences, Consulting Fees I will be discussing non-fda approved
More informationDr. David James PINATO MD MRCP (UK) MRes PhD
European HIV Hepatitis Co-infection (EHHC) Conference 10-11 December 2015, London Plenary Session 4: Hepatitis B L i v e r C a n c e r P a t h o g e n e s i s, S c r e e n i n g & Tr e a t m e n t Dr.
More informationMolecular signature for management of hepatocellular carcinoma
Molecular signature for management of hepatocellular carcinoma Yujin Hoshida, MD, PhD Liver Cancer Program, Tisch Cancer Institute Division of Liver Diseases, Department of Medicine Icahn School of Medicine
More informationHepatocellular Carcinoma for NNN Cancer Webinar Series
Hepatocellular Carcinoma for NNN Cancer Webinar Series Brian J McMahon, MD Liver Disease and Hepatitis Program Alaska Native Tribal Health Consortium * None Disclosures Outline of Talk * Epidemiology of
More informationSorafenib for Egyptian patients with advanced hepatocellular carcinoma; single center experience
Journal of the Egyptian National Cancer Institute (2014) 26, 9 13 Cairo University Journal of the Egyptian National Cancer Institute www.nci.cu.adu.eg www.sciencedirect.com Original article Sorafenib for
More informationNovel Molecular Molecular Therapies In Hepatocarcinoma Prof Eric
Novel Molecular Therapies In Hepatocarcinoma Prof. Eric Raymond Department of Médical Oncology Hôpital Beaujon, Clichy Université Paris 7 Denis Diderot INSERM-U728 eric.raymond@bjn.aphp.fr HCC is a highly
More informationRESEARCH ARTICLE. Validation of The Hong Kong Liver Cancer Staging System in Patients with Hepatocellular Carcinoma after Curative Intent Treatment
DOI:10.22034/APJCP.2017.18.6.1697 RESEARCH ARTICLE Validation of The Hong Kong Liver Cancer Staging System in Patients with Hepatocellular Carcinoma after Curative Intent Treatment Alan Chuncharunee 1,
More informationA New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib
Published online: March 9, 2017 Editorial A New Era of Systemic Therapy for Hepatocellular Carcinoma with Prof. M. Kudo Editor Liver Cancer Introduction The SHARP study in 2007 [1] and the Asia Pacific
More informationChemotherapy-induced HBV reactivation in cancer patients
Chemotherapy-induced HBV reactivation in cancer patients On behalf of Taiwan Cooperative Oncology Group (TCOG) HBV reactivation in lymphoma patients: What we have known HBV reactivation and hepatitis flares
More informationLiver Cancer: Diagnosis and Treatment Options
Liver Cancer: Diagnosis and Treatment Options Fred Poordad, MD Chief, Hepatology University Transplant Center Professor of Medicine UT Health, San Antonio VP, Academic and Clinical Affairs, Texas Liver
More informationOptimizing Patient Selection, Organ Allocation, and Outcomes in Liver Transplant (LT) Candidates with Hepatocellular Carcinoma (HCC)
XXVI SETH Congress- 30 November 2017 Optimizing Patient Selection, Organ Allocation, and Outcomes in Liver Transplant (LT) Candidates with Hepatocellular Carcinoma (HCC) Neil Mehta, MD University of California,
More informationUPDATE TO THE MANAGEMENT OF PATIENTS WITH HCC HCA
UPDATE TO THE MANAGEMENT OF PATIENTS WITH HCC HUSSEIN K. MOHAMED MD, FACS. Transplant and Hepato-biliary Surgery Largo Medical Center HCA DISCLOSURE I have no financial relationship(s) relevant to the
More informationStudy Objective and Design
Randomized, Open Label, Multicenter, Phase II Trial of Transcatheter Arterial Chemoembolization (TACE) Therapy in Combination with Sorafenib as Compared With TACE Alone in Patients with Hepatocellular
More informationViral Hepatitis. Dr Melissa Haines Gastroenterologist Waikato Hospital
Viral Hepatitis Dr Melissa Haines Gastroenterologist Waikato Hospital Viral Hepatitis HAV HBV HCV HDV HEV Other viral: CMV, EBV, HSV Unknown Hepatitis A Hepatitis A Transmitted via the faecal-oral route
More informationImmunotherapy of Hepatocellular Carcinoma Where are we now?
Immunotherapy of Hepatocellular Carcinoma Where are we now? KLCSG, Jan 30, 2016, Seoul Ann-Lii Cheng M.D., Ph.D. Distinguished Professor and Director, NTU Cancer Center, National Taiwan University, Taipei,
More information